Ozanimod
Written and reviewed by Dr Ibrahim Imam, Consultant Neurologist. Last reviewed .
Ozanimod. Ozanimod is a sphingosine-1-phosphate receptor (S1PR) modulator. Fully referenced neurology checklist.
Pharmacology
- Ozanimod is a sphingosine-1-phosphate receptor (S1PR) modulator
- It sequesters lymphocytes within lymph nodes
- It acts on S1PR1 and S1PR5
Indications
Locked: subscribe to see this section.
Benefits
Locked: subscribe to see this section.
Dosing
Locked: subscribe to see this section.
Side effects
Locked: subscribe to see this section.
Pre-treatment precautions
Locked: subscribe to see this section.
Contraindications
Locked: subscribe to see this section.
Complications
Locked: subscribe to see this section.
Acronym
Locked: subscribe to see this section.
References
- Lamb YN. Ozanimod: first approval. Drugs 2020 (Epub ahead of print).
- Chaudhry BZ, Cohen JA, Conway DS. Sphingosine 1-phosphate receptor modulators for the treatment of multiple sclerosis. Neurotherapeutics 2017; 14:859-873.
- Derfuss T, Mehling M, Papadopoulou A, Bar-Or A, Cohen JA, Kappos L. Advances in oral immunomodulating therapies in relapsing multiple sclerosis. Lancet Neurol 2020; 19:336-347.
- Comi G, Kappos L, Selmaj KW, et al; SUNBEAM Study Investigators. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. Lancet Neurol 2019; 18:1009-1020.
- Cohen JA, Arnold DL, Comi G, et al; RADIANCE Study Group. Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial. Lancet Neurol 2016; 15:373-381.
- And 1 more. Subscribe to see the full list
